Reporting AIDS - New HIV Treatment: Maraviroc
About this Video
Reporting AIDS focuses on the people, policies and issues facing the global community. Shows appear twice a month with in-depth interviews conducted by host John Mikytuck.
Past episodes can be viewed here.
The Food and Drug Administration announced the approval of a new HIV treatment called Maraviroc in August 2007. Maraviroc is the first of an entirely new class of HIV treatments called Entry Inhibitors. Entry inhibitors work by blocking the entry of HIV into a healthy CD4 cell. This new class of HIV drugs offers another option for people infected with HIV that have become resistant to other classes of HIV medications. Maraviroc targets one of two receptors on the CD4 cell that HIV first attaches itself too before it an infect the cell. The receptor is called CCR5.
Mark Milano, Health Educator at the AIDS Community Research Institute of America, and Dr. Pete Gordon, HIV/AIDS expert from Columbia University, join Reporting AIDS to discuss Maraviroc.
Discussion
No comments for “Reporting AIDS - New HIV Treatment: Maraviroc”
Post a comment